PRTA — PROTHENA CORP PUBLIC LTD CO
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1559053 ·
Last close
$8.12
Market Cap
$425.11M
52W High
$11.80
52W Low
$7.73
ADV30
625,433
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 51,084,000 | — | 25,791,000 | 32,721,000 | 349,894,000 | 329,462,000 | 37,278,000 |
| Dec 2025 | 21,000 | — | -27,211,000 | -21,589,000 | 326,804,000 | 307,531,000 | 46,330,000 |
| Sep 2025 | 2,415,000 | — | -39,761,000 | -36,541,000 | 352,628,000 | 330,843,000 | 57,639,000 |
| Jun 2025 | 4,420,000 | — | -52,007,000 | -125,767,000 | 399,066,000 | 371,435,000 | 74,735,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-163,580,000
Investing CF
$-138,000
Financing CF
$-139,000
CapEx
$-181,000
Dividends Paid
—
Buybacks
$-139,000
EPS Diluted TTM
$-4.54
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,346,433,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-184,560,000
Pretax Income TTM
$-200,829,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$57,940,000
EBITDA
$-92,332,000
Free Cash Flow
$-31,584,500
Enterprise Value
$103,300,288
Total Cash
$329,462,016
Total Debt
$7,654,000
Shares Out
52,353,237
Trailing EPS
$-2.81
Book Value
$5.89
ROE
-40.3%
ROA
-13.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,684,000 | -184,560,000 | -244,092,000 | 326,804,000 | 46,330,000 | — | -163,580,000 |
| Dec 2024 | 135,157,000 | -154,561,000 | -122,310,000 | 547,108,000 | 60,182,000 | — | -150,050,000 |
| Dec 2023 | 91,370,000 | -191,036,000 | -147,028,000 | 696,382,000 | 135,017,000 | — | -133,906,000 |
| Dec 2022 | 53,905,000 | -131,557,000 | -116,949,000 | 758,035,000 | 135,993,000 | — | -108,821,000 |
TTM Snapshot
Revenues TTM
$226,527,000
NetIncome TTM
$26,389,000
OpCashFlow TTM
$0
Assets (Latest)
$547,108,000
Forward EPS
$-1.31
Max Pain — expiry 2026-12-18
max pain strike: $10.00 · spot: $8.12 · call oi: 2,240 · put oi: 2,331Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $418.09M | $6.40 | — |
| SGMT | Sagimet Biosciences Inc. | $435.02M | $7.11 | — |
| OVID | Ovid Therapeutics Inc. | $414.34M | $2.22 | — |
| KMDA | KAMADA LTD | $411.94M | $7.14 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $409.30M | $0.38 | — |
News headlines (Yahoo Finance, 1h cache)
Prothena to Report Second Quarter 2026 Financial Results on August 6
2026-07-30 20:05 · Yahoo
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?
2026-07-09 15:38 · Yahoo
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
2026-06-12 09:44 · Yahoo
High Insider Ownership Growth Stocks To Watch In May 2026
2026-05-28 17:35 · Yahoo
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
2026-05-11 13:17 · Yahoo
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
2026-04-29 22:07 · Yahoo
3 Growth Companies Insiders Are Eager To Hold
2026-04-29 11:36 · Yahoo
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
2026-04-01 15:04 · Yahoo
Top Growth Companies With High Insider Ownership In March 2026
2026-03-31 17:36 · Yahoo
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
2026-03-31 16:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.